AIM: Ten percent of soft @entity242 (STS) arise in the retroperitoneal tissues. The prognosis for @entity1 with @entity242 is poor with a 5-year survival rate between 12% and 70%. Stage at presentation, high histological grade, unresectable primary @entity5 and incomplete resection are associated with a less favourable outcome. METHODS: Complete follow-up data were available on 22 @entity1 who underwent surgery for retroperitoneal STS in our institution between 1990 and 2000. @entity1 , @entity5 and treatment variables were analysed including use of adjuvant therapy and survival status. RESULTS: Eighteen @entity1 underwent surgery for primary disease, four @entity1 were treated for recurrent disease or @entity3 . Ten @entity1 presented with @entity158 , seven with an abdominal mass, other presentation included @entity353 and haematuria. Thirteen @entity1 presented with @entity5 larger than 10 cm. The @entity5 were @entity1821 , @entity1822 , three malignant @entity82 , two @entity980 , two @entity5 and two undifferentiated @entity242 . Six primary @entity5 were completely excised, five @entity1 received radiotherapy and five received chemotherapy. Local recurrence rate was 45% and recurrence-free interval for 10 @entity1 with recurrence was 11 months. Five @entity1 received radiotherapy and five received chemotherapy. The median survival for @entity1 with primary @entity5 was 36 months, and 5-year survival was 44%. Adjuvant therapy was not associated with higher survival rates. CONCLUSION: This study re-emphasizes the poor outcome of @entity1 with retroperitoneal STS. Adjuvant radiotherapy and chemotherapy do not appear to be any proven benefit and the single most important prognostic factor is aggressive successful en bloc resection of the primary @entity5 . Our resection rate and 5-year survival rates are comparable with previous reported UK series although lower than large reports from North American centres. This might partly be explained by difficulty in data collection in a retrospective analysis, but may reflect inadequate subspecialization in UK centres.

The management of XXXX : a single institution experience with a review of the literature.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrous histiocytomas'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas', 'retroperitoneal sarcoma', 'tissue sarcomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'malignant schwannomas', 'tumour'] @entity1822 :: ('MESH:D007890', 'Disease') :: ['six leiomyosarcomas'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcomas'] @entity1821 :: ('MESH:D008080', 'Disease') :: ['seven liposarcomas']
@entity242 :: (MESH:D012509,Disease) :: ['retroperitoneal soft tissue sarcoma']
